Bluebird Bio | BLUE - Capital De Empréstimo



Capital De Empréstimo Alterar Data
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
Amgen USD 50B 2.43B 2025-12
Arrowhead Research USD 538.1M 323.22M 2025-12
Biogen USD 6.29B 1.4M 2025-09
BioMarin Pharmaceutical USD 597.18M 513K 2025-12
Gilead Sciences USD 22.14B 5M 2025-09
Incyte USD 30.2M 5.17M 2025-12
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
Moderna USD 610M 584M 2025-12
Nektar Therapeutics USD 107.51M 10.35M 2024-06
Novartis USD 24.24B 174M 2025-09
Pfizer USD 57.41B 93M 2025-09
PTC Therapeutics USD 2.03B 193.22M 2025-12
Regeneron Pharmaceuticals USD 2.71B 720.4M 2025-12
Sangamo BioSciences USD 0 0 2022-06
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
Tectonic Therapeutic USD 100K 86K 2025-09
Ultragenyx Pharmaceutical USD 763.74M 19.02M 2025-09
Vertex Pharmaceuticals USD 111.4M 1.4M 2025-03